Topological analysis of the power grid and mitigation strategies against cascading failures

This paper presents a complex systems overview of a power grid network. In recent years, concerns about the robustness of the power grid have grown because of several cascading outages in different parts of the world. In this paper, cascading effect has been simulated on three different networks, the IEEE 300 bus test system, the IEEE 118 bus test system, and the WSCC 179 bus equivalent model, using the DC Power Flow Model. Power Degradation has been discussed as a measure to estimate the damage to the network, in terms of load loss and node loss. A network generator has been developed to generate graphs with characteristics similar to the IEEE standard networks and the generated graphs are then compared with the standard networks to show the effect of topology in determining the robustness of a power grid. Three mitigation strategies, Homogeneous Load Reduction, Targeted Range-Based Load Reduction, and Use of Distributed Renewable Sources in combination with Islanding, have been suggested. The Homogeneous Load Reduction is the simplest to implement but the Targeted Range-Based Load Reduction is the most effective strategy.Comment: 5 pages, 8 figures, 1 table. This is a limited version of the work due to space limitations of the conference paper. A detailed version is submitted to the IEEE Systems Journal and is currently under revie

Standardizacija hrvatskog jezika i stvaranje nacionaliziranih političkih subjekata kroz jezik? Pogled iz očišta društvenih i humanističkih znanosti

This paper focuses on language policy and social changes which have taken place in Croatia during and since the 1991-5 war. I first describe the historical background, the war and the nineties being marked by excesses of linguistic purism and prescriptivism, alongside the formation of post-Yugoslav states in which national belonging was key to defining citizenship. Through examining the relationship between changing linguistic and social orders, I raise a number of issues for discussion. I argue that the legal framework of minority language rights has consolidated and legitimated a nationalist imaginary, increasing social divisions and reinforcing hierarchies asserted by some nationalists between national categories. For this reason, I suggest that the uncritical endorsement of or promotion of linguistic diversity can be dangerous. Second, in an activist-anthropological vein, I discuss possible reasons why academics trained in the social sciences and humanities have rarely participated in sociolinguistic debates concerning the new Croatian standard. I suggest such discussions could greatly benefit from interventions by social scientists, so as to bring sociolinguistics into contact with other strands of the social sciences and humanities and move away from what I believe to be a problematic policy focus on "identity".Ovaj se rad bavi jezičnom politikom i društvenim promjenama koje su se dogodile u Hrvatskoj za vrijeme i nakon rata koji je trajao od 1991. do 1995. godine. Počinjem opisom povijesne pozadine, rata i devedesetih godina 20. stoljeća, koje je obilježila velika količina jezičnog purizma i preskriptivizma u Hrvatskoj te stvaranje postjugoslavenskih država u kojima je pripadanje naciji predstavljalo ključ za definiranje državljanstva. Istraživanjem odnosa između promjena u jezičnom i društvenom poretku, problematiziram više tema. Tvrdim da je zakonski okvir prava manjinskog jezika osnažio i legitimizirao nacionalistički imaginarij, stvarajući daljnje društvene podjele i učvršćujući hijerarhije koje među nacionalnim kategorijama promoviraju određeni nacionalisti. Iz tog razloga, tvrdim da nekritičko odobravanje ili promoviranje lingvističke različitosti mogu biti opasni. Nadalje, u aktivističko-antropološkom smislu, razlažem moguće razloge zbog kojih su znanstvenici društvenih i humanističkih znanosti rijetko sudjelovali u sociolingvističkim raspravama koje se tiču novog hrvatskog standardnog jezika. Tvrdim da bi takvim raspravama u znatnoj mjeri doprinijelo sudjelovanje znanstvenika humanističkih i društvenih znanosti, jer bi se stvorila veza između sociolingvistike i ostalih grana humanističkih i društvenih znanosti te bi se tako odmaknuli od, prema mojem sudu problematične, politike usredotočene na "identitet"

Croatian Language Standardization and the Production of Nationalized Political Subjects through Language? Perspectives from the Social Sciences and Humanities

This paper focuses on language policy and social changes which have taken place in Croatia during and since the 1991-5 war. I first describe the historical background, the war and the nineties being marked by excesses of linguistic purism and prescriptivism, alongside the formation of post-Yugoslav states in which national belonging was key to defining citizenship. Through examining the relationship between changing linguistic and social orders, I raise a number of issues for discussion. I argue that the legal framework of minority language rights has consolidated and legitimated a nationalist imaginary, increasing social divisions and reinforcing hierarchies asserted by some nationalists between national categories. For this reason, I suggest that the uncritical endorsement of or promotion of linguistic diversity can be dangerous. Second, in an activist-anthropological vein, I discuss possible reasons why academics trained in the social sciences and humanities have rarely participated in sociolinguistic debates concerning the new Croatian standard. I suggest such discussions could greatly benefit from interventions by social scientists, so as to bring sociolinguistics into contact with other strands of the social sciences and humanities and move away from what I believe to be a problematic policy focus on "identity"

Genetic Control of Organ Shape and Tissue Polarity

A combination of experimental analysis and mathematical modelling shows how the genetic control of tissue polarity plays a fundamental role in the development and evolution of form

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

Background From early in the COVID-19 pandemic, evidence suggested a role for cytokine dysregulation and complement activation in severe disease. In the TACTIC-R trial, we evaluated the efficacy and safety of baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, and ravulizumab, a monoclonal inhibitor of complement C5 activation, as an adjunct to standard of care for the treatment of adult patients hospitalised with COVID-19. Methods TACTIC-R was a phase 4, randomised, parallel-arm, open-label platform trial that was undertaken in the UK with urgent public health designation to assess the potential of repurposing immunosuppressants for the treatment of severe COVID-19, stratified by a risk score. Adult participants (aged ≥18 years) were enrolled from 22 hospitals across the UK. Patients with a risk score indicating a 40% risk of admission to an intensive care unit or death were randomly assigned 1:1:1 to standard of care alone, standard of care with baricitinib, or standard of care with ravulizumab. The composite primary outcome was the time from randomisation to incidence (up to and including day 14) of the first event of death, invasive mechanical ventilation, extracorporeal membrane oxygenation, cardiovascular organ support, or renal failure. The primary interim analysis was triggered when 125 patient datasets were available up to day 14 in each study group and we included in the analysis all participants who were randomly assigned. The trial was registered on ClinicalTrials.gov (NCT04390464). Findings Between May 8, 2020, and May 7, 2021, 417 participants were recruited and randomly assigned to standard of care alone (145 patients), baricitinib (137 patients), or ravulizumab (135 patients). Only 54 (39%) of 137 patients in the baricitinib group received the maximum 14-day course, whereas 132 (98%) of 135 patients in the ravulizumab group received the intended dose. The trial was stopped after the primary interim analysis on grounds of futility. The estimated hazard ratio (HR) for reaching the composite primary endpoint was 1·11 (95% CI 0·62–1·99) for patients on baricitinib compared with standard of care alone, and 1·53 (0·88–2·67) for ravulizumab compared with standard of care alone. 45 serious adverse events (21 deaths) were reported in the standard-of-care group, 57 (24 deaths) in the baricitinib group, and 60 (18 deaths) in the ravulizumab group. Interpretation Neither baricitinib nor ravulizumab, as administered in this study, was effective in reducing disease severity in patients selected for severe COVID-19. Safety was similar between treatments and standard of care. The short period of dosing with baricitinib might explain the discrepancy between our findings and those of other trials. The therapeutic potential of targeting complement C5 activation product C5a, rather than the cleavage of C5, warrants further evaluation

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Abstract Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

INVESTIGATING THE ROLES OF HISTONE RESIDUES, CHAPERONES, AND MODIFIERS IN CHROMATIN REGULATION, CHROMATIN DYNAMICS, AND DNA EXCISION REPAIR

In a eukaryotic cell, DNA is packaged into chromatin, a highly dynamic and highly regulated structure. Chromatin is composed of nucleosome subunits, comprised of an octamer of histone proteins wrapped by DNA. Histone proteins are highly conserved among species, and also show a high degree of post-translational modification. In this work, we sought to better understand the roles of histone residues, histone domains, and histone modification in chromatin regulation and dynamics using Saccharomyces cerevisiae as a model eukaryote. In part one of this dissertation, we examine key residues and domains of histone proteins and how they interact with the cellular environment. First, we determined the “sprocket” arginine residues that project into the minor groove of DNA as it wraps around the histone octamer are important for cell viability, histone occupancy, gene expression and DNA repair. Second, we determined the nucleosome acidic patch that forms a negatively charged surface in the solvent-exposed region of the nucleosome is important for histone occupancy and binding to the essential histone chaperone FACT. Third, we found the histone H2B repression (HBR) domain in the H2B N-terminal tail is important for FACT binding and DNA damage resistance. Collectively, these studies increase our understanding of how unique features in histone structure regulate chromatin structure and interactions. In part two of this dissertation, we examine the roles of essential chromatin-associated factors in response to DNA damage. During the DNA damage response, chromatin must be transiently remodeled in order for DNA repair to occur. However, the roles of specific chromatin factors in the DNA damage response are still being elucidated. We optimized the anchor-away method to conditionally deplete essential chromatin factors from the yeast cell nucleus, and discovered the NuA4 histone acetyltransferase complex plays an important role in DNA excision repair. These studies highlight the role of essential chromatin factors in repairing DNA lesions

Investigation of antennas and energy harvesting methods for use with a UHF microtransceiver in a biosensor network

Master of ScienceDepartment of Electrical and Computer EngineeringWilliam B. KuhnThis work was a part of NASA EPSCoR Project NNX11AM05A: Biosensor Networks and Telecommunication Subsystems for Long Duration Missions, EVA Suits, and Robotic Precursor Scout Missions. The project’s main goal is the development of a wireless sensor network inside an astronaut’s spacesuit. Antennas are essential components in a wireless network. Since this antenna will be used inside the spacesuit it is important to consider both the physical size limitations and the desired antenna polarization. After exploring the WWVB radio station antenna which provides the preferred vertical polarization and has a suitable aspect ratio, the top hat antenna seemed promising for intrasuit communication. The design of a top hat antenna is outlined. Then, the antennas were tested using 433 MHz radios in a full scale model spacesuit. This spacesuit was designed specifically to model the behavior of aluminized mylar in the real suit. Test results support the feasibility of an intrasuit wireless network. If a gateway radio is placed on the chest or back, a sensor could be placed anywhere on the body and provide an adequate signal. These initial tests did not include a matching network, but the additional link-margin afforded by a matching network, even an imperfect match, is considered. Energy harvesting is explored as an alternative to batteries powering the intrasuit radio. In the oxygen rich environment of a spacesuit, even the smallest spark can be catastrophic. A variety of energy harvesting options are explored with a focus on thermal energy harvesting. The temperature difference between the human skin and the astronaut’s Liquid Cooling and Ventilation Garment can be used to produce a small voltage. To increase the voltage a step-up converter is implemented. Final integration of the two systems with a biosensor is left for on-going work in the three year NASA project